. 2021 Aug 23;12:723196. doi: 10.3389/fimmu.2021.723196

Table 3.

Summary of significant differentially expressed genes (absolute fold-change ≥2; FDR ≤0.05) in peripheral blood mononuclear cells between: A) HIV/HCV-coinfected at week 36 after SVR (HIV/HCV-f) versus HIV/HCV-coinfected at baseline (HIV/HCV-b). B) HIV/HCV-coinfected at week 36 after SVR (HIV/HCV-f) versus HCV-monoinfected at week 36 after SVR (HCV-mono-f); C) HIV/HCV-coinfected at week 36 after SVR (HIV/HCV-f) and HIV-monoinfected (HIV-mono).

A) HIV/HCV-f versus HIV/HCV-b					B) HIV/HCV-f versus HCV-mono-f					C) HIV/HCV-f versus HIV-mono
Gene symbol	FC	Log₂ (FC)	p-value *	q-value **	Gene symbol	FC	Log₂ (FC)	p-value *	q-value **	Gene symbol	FC	Log₂ (FC)	p-value *	q-value **
*HAS1*	2.99	1.58	≤ 0.001	≤ 0.001	*CD8A*	3.46	1.79	≤ 0.001	≤ 0.001	*IL1A*	4.72	2.24	0.009	0.026
*IRG1*	2.16	1.11	0.009	0.036	*TRGV2*	3.35	1.75	≤ 0.001	0.031	*TNFAIP6*	4.39	2.13	≤0.001	≤0.001
*IFIT3*	0.48	-1.07	≤0.001	≤0.001	*CD8B*	3.06	1.61	≤0.001	≤0.001	*SERPINB2*	3.79	1.92	0.002	0.007
*MX1*	0.47	-1.08	≤0.001	≤0.001	*LAG3*	2.59	1.37	≤0.001	0.003	*OLR1*	3.41	1.77	0.019	0.048
*IFI6*	0.47	-1.09	≤0.001	≤0.001	*TNFRSF13C*	2.41	1.27	≤0.001	0.020	*CCL20*	3.36	1.75	0.007	0.021
*ADARB2*	0.47	-1.09	≤0.001	≤0.001	*KLRK1*	2.05	1.03	≤0.001	0.019	*SIK1*	2.75	1.46	0.005	0.016
*RRAD*	0.46	-1.11	≤0.001	0.001	*IFNLR1*	2.02	1.02	≤0.001	0.007	*CXCL8*	2.65	1.41	0.002	0.009
*IFI44*	0.38	-1.41	≤0.001	≤0.001	*CDKN2A*	2.01	1.01	≤0.001	0.019	*KCNMA1*	2.64	1.40	≤0.001	0.001
*IFIT1*	0.37	-1.45	≤0.001	≤0.001	*CD180*	0.47	-1.10	≤0.001	0.024	*TNFSF15*	2.57	1.36	0.003	0.012
*IFIT1B*	0.34	-1.55	0.009	0.035	*CDKN1C*	0.46	-1.13	≤0.001	0.026	*CXCL3*	2.54	1.34	0.013	0.036
*CCL7*	0.34	-1.57	≤0.001	0.003	*FCGR3A*	0.45	-1.17	≤0.001	0.015	*LAMB3*	2.50	1.32	0.019	0.047
*CCL8*	0.33	-1.62	0.001	0.004	*SEMA3A*	0.41	-1.29	≤0.001	0.009	*CFD*	2.40	1.27	≤0.001	≤0.001
*CCL2*	0.27	-1.87	≤0.001	≤0.001	*NRXN2*	0.39	-1.37	≤0.001	0.019	*CD68*	2.39	1.26	≤0.001	≤0.001
*SIGLEC1*	0.22	-2.17	≤0.001	≤0.001	*CEACAM3*	0.38	-1.41	0.001	0.037	*EDN3*	2.34	1.23	0.004	0.013
*IFI44L*	0.21	-2.24	≤0.001	≤0.001	*CX3CR1*	0.37	-1.42	≤0.001	0.017	*DSP*	2.33	1.22	0.016	0.042
*CXCL11*	0.18	-2.45	≤0.001	≤0.001	*FAT4*	0.35	-1.53	≤0.001	≤0.001	*LRG1*	2.31	1.21	≤0.001	≤0.001
*IFI27*	0.09	-3.42	≤0.001	≤0.001	*PPP1R17*	0.28	-1.86	≤0.001	0.019	*FOXD2*	2.28	1.19	≤0.001	≤0.001
										*CCDC85B*	2.26	1.18	≤0.001	≤0.001
										*FANCL*	2.18	1.12	≤0.001	≤0.001
										*RNF144B*	2.13	1.09	≤0.001	≤0.001
										*FKBP1C*	2.11	1.08	≤0.001	≤0.001
										*CDKN2A*	2.08	1.06	≤0.001	≤0.001
										*CAVIN3*	2.06	1.04	≤0.001	0.001
										*ADAT3*	2.03	1.02	≤0.001	≤0.001
										*TNFSF9*	2.01	1.01	0.001	0.003
										*TRAV25*	0.50	-1.00	≤0.001	≤0.001
										*EDAR*	0.49	-1.04	0.002	0.007
										*PARD3*	0.49	-1.04	≤0.001	0.001
										*CNTNAP1*	0.49	-1.04	≤0.001	≤0.001
										*PF4V1*	0.48	-1.05	≤0.001	0.002
										*CMTM5*	0.48	-1.06	≤0.001	0.001
										*HAVCR1*	0.48	-1.07	≤0.001	≤0.001
										*ALOX12*	0.47	-1.10	≤0.001	≤0.001
										*FSTL1*	0.46	-1.13	≤0.001	≤0.001
										*PDZD2*	0.45	-1.14	≤0.001	≤0.001
										*PF4*	0.45	-1.17	≤0.001	≤0.001
										*IGKV1-5*	0.44	-1.19	0.007	0.023
										*GP1BA*	0.44	-1.20	≤0.001	≤0.001
										*CLEC4F*	0.43	-1.20	0.007	0.022
										*COL5A3*	0.41	-1.27	0.006	0.019
										*ADARB2*	0.36	-1.46	0.001	0.005
										*ROBO1*	0.35	-1.51	≤0.001	≤0.001
										*IGLV8-61*	0.24	-2.06	0.010	0.030
										*IGLV2-23*	0.20	-2.29	0.010	0.029
										*IGLV2-18*	0.20	-2.34	0.004	0.012
										*IGHG2*	0.10	-3.37	0.003	0.010

Values are expressed as fold-change (FC) and its log₂. (*), raw p-values; (**), p-values corrected for multiple testing using the false discovery rate (FDR) with Benjamini and Hochberg procedure.

HCV, hepatitis C virus; HIV, human immunodeficiency virus; HIV/HCV-f, HIV/HCV-coinfected at week 36 after SVR; HIV/HCV-b, HIV/HCV-coinfected at baseline; HCV-mono-f, HCV-monoinfected at week 36 after SVR; HIV-mono, HIV-monoinfected patients.